JAKAFI (RUXOLITINIB PHOSPHATE)
- Myelofibrosis
- Polycythemia vera
- Thrombocytosis in myeloproliferative disease
- Graft versus host disease
10 mg tablet
- 1 tablet (10 mg) by oral route 2 times per day
15 mg tablet
- 1 tablet (15 mg) by oral route 2 times per day
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
25 mg tablet
- 1 tablet (25 mg) by oral route 2 times per day
5 mg tablet
- 1 tablet (5 mg) by oral route 2 times per day
Graft versus host disease
- 1 tablet (5 mg) by oral route 2 times per day
- 1 tablet (5 mg) by oral route once daily
- 1 tablet (10 mg) by oral route 2 times per day
- 2 tablets (10 mg) by oral route 2 times per day
Myelofibrosis
- 1 tablet (5 mg) by oral route 2 times per day
- 1 tablet (5 mg) by oral route once daily
- 1 tablet (10 mg) by oral route 2 times per day
- 2 tablets (10 mg) by oral route 2 times per day
- 1 tablet (15 mg) by oral route 2 times per day
- 2 tablets (20 mg) by oral route 2 times per day
- 1 tablet (20 mg) by oral route 2 times per day
- 1 tablet (25 mg) by oral route 2 times per day
Polycythemia vera
- 1 tablet (5 mg) by oral route 2 times per day
- 1 tablet (5 mg) by oral route once daily
- 1 tablet (10 mg) by oral route 2 times per day
- 2 tablets (10 mg) by oral route 2 times per day
- 1 tablet (15 mg) by oral route 2 times per day
- 2 tablets (20 mg) by oral route 2 times per day
- 1 tablet (20 mg) by oral route 2 times per day
- 1 tablet (25 mg) by oral route 2 times per day
Thrombocytosis in myeloproliferative disease
- 1 tablet (5 mg) by oral route 2 times per day
- 1 tablet (5 mg) by oral route once daily
- 1 tablet (10 mg) by oral route 2 times per day
- 2 tablets (10 mg) by oral route 2 times per day
- 1 tablet (15 mg) by oral route 2 times per day
- 2 tablets (20 mg) by oral route 2 times per day
- 1 tablet (20 mg) by oral route 2 times per day
- 1 tablet (25 mg) by oral route 2 times per day
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
- Progressive multifocal leukoencephalopathy
- Thromboembolic disorder
Contraindicated
- Active tuberculosis
- Anemia
- Child-pugh class A hepatic impairment
- Child-pugh class B hepatic impairment
- Child-pugh class C hepatic impairment
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Neutropenic disorder
- Severe infection
- Thrombocytopenic disorder
Severe
Moderate
- Basal cell carcinoma of skin
- Kidney disease with likely reduction in GFR
- Merkel cell carcinoma
- Squamous cell carcinoma
JAKAFI (RUXOLITINIB PHOSPHATE)
- Myelofibrosis
- Polycythemia vera
- Thrombocytosis in myeloproliferative disease
- Graft versus host disease
- Abnormal hepatic function tests
- Anemia
- Neutropenic disorder
- Thrombocytopenic disorder
- Acute abdominal pain
- Bruising
- Diarrhea
- Dizziness
- Dyspnea
- Fatigue
- Headache disorder
- Hypercholesterolemia
- Muscle spasm
More Frequent
Severe
Less Severe
- Herpes zoster
- Hypertension
- Increased alanine transaminase
- Increased aspartate transaminase
- Infection
- Thrombotic disorder
- Constipation
- Cough
- Edema
- Epistaxis
- Flatulence
- Pharyngitis
- Skin rash
- Urinary tract infection
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Active tuberculosis
- Bacterial infection
- Opportunistic fungal infection
- Progressive multifocal leukoencephalopathy
- Viral infection
Less Severe
- Basal cell carcinoma of skin
- Hypertriglyceridemia
- Merkel cell carcinoma
- Squamous cell carcinoma
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Ruxolitinib
Safety and efficacy not established for age < 12 years. Increased risk of bone fractures seen in animal studies.
- 1 Day – 12 Years
- Safety and efficacy not established for age < 12 years. Increased risk of bone fractures seen in animal studies.
Ruxolitinib
- Severity Level:
C
- Additional Notes: Insufficient human data avail; animal data show decreased fetal weight 2x mrhd
Contraindicated
Ruxolitinib
Insufficient human data; potential for serious adverse effects; excr. in rats
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient human data; potential for serious adverse effects; excr. in rats |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Ruxolitinib
Renal-Dose adjustment is required for CrCL<60 mL/min. Hepatic-Dose adjustment required for any hepatic impairment. Consider the hepatic impairment of aging. Cardiovascular-Increased thrombosis risk and mortality risk in patients aged 50 years and older with underlying cardiovascular conditions.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | Y | Y | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
Graft versus host disease | |
D89.81 | Graft-versus-host disease |
D89.810 | Acute graft-versus-host disease |
D89.811 | Chronic graft-versus-host disease |
D89.812 | Acute on chronic graft-versus-host disease |
D89.813 | Graft-versus-host disease, unspecified |
Myelofibrosis | |
D47.4 | Osteomyelofibrosis |
D75.81 | Myelofibrosis |
Polycythemia vera | |
D45 | Polycythemia vera |
Thrombocytosis in myeloproliferative disease | |
D47.1 | Chronic myeloproliferative disease |
D47.3 | Essential (hemorrhagic) thrombocythemia |
0-9 | A-Z |
---|---|
D45 | Polycythemia vera |
D47.1 | Chronic myeloproliferative disease |
D47.3 | Essential (hemorrhagic) thrombocythemia |
D47.4 | Osteomyelofibrosis |
D75.81 | Myelofibrosis |
D89.81 | Graft-versus-host disease |
D89.810 | Acute graft-versus-host disease |
D89.811 | Chronic graft-versus-host disease |
D89.812 | Acute on chronic graft-versus-host disease |
D89.813 | Graft-versus-host disease, unspecified |